1	
2	
3	
4	Clinical value of the fibrosis-4 index in predicting mortality in patients with right
5	ventricular pacing
6	
7	Short title: FIB-4 for predicting pacemaker patient mortality
8	
9	Naoya Inoue ^{1, 2*} , Shuji Morikawa ^{1, 2} , Takashi Ogane ¹ , Takehiro Hiramatsu ^{1, 2} , Toyoaki Murohara ²
10	
11	¹ Department of Cardiology, Chutoen General Medical Center, Kakegawa, Shizuoka, Japan
12	² Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Aichi,
13	Japan
14	
15	*Corresponding author
16	E-mail: inouenaoya251410@gmail.com (NI)
17	

2

18 Abstract

Background: The fibrosis-4 (FIB-4) index has attracted attention as a predictive factor for cardiovascular events and mortality in patients with heart disease. However, its clinical value in patients with implanted pacemakers remains unclear.

Methods: This study included patients who underwent pacemaker implantation. The FIB-4 index was calculated based on blood tests performed during the procedure. The primary outcome was all-cause mortality, and secondary outcomes included cardiovascular and non-cardiovascular death. The FIB-4 index was stratified into tertiles. Between-group comparisons were performed using log-rank tests and multivariate analysis using Cox proportional hazards. The predictive accuracy and cut-off value of the FIB-4 index were calculated from the receiver operating characteristic curve for all-cause mortality.

29 Results: This study included 201 participants, of whom 38 (incidence rate: 5.8/100 person-years) 30 experienced death events during the observation period (median: 1097 days). All-cause and non-31 cardiovascular death differed significantly between groups stratified by the FIB-4 index tertiles 32 (log-rank test: P<0.001 and P<0.001, respectively). Using Cox proportional hazards analysis, the 33 unadjusted hazard ratio was 4.75 (95% confidence interval [CI]: 2.05–11.0, P<0.001) for Tertile 34 3 compared to Tertile 1. After adjustment for confounding factors, including age, sex, the presence 35 or absence of left bundle branch block at baseline, QRS duration during pacing, and pacing rate 36 at the last check, the hazard ratio was 3.61 (95% CI: 1.37–9.48, P=0.009). The cut-off of the FIB-4 index was 3.75 (area under the curve: 0.72, 95% CI: 0.62–0.82). 37

Conclusions: The FIB-4 index was a potential predictive factor for all-cause mortality in patients
 with implanted pacemakers.

40 Introduction

41 In the past, right ventricular pacing (RVP) was used for bradycardia arrhythmias; however, this 42 was associated with problems like decreased left ventricular systolic function [1], increased 43 hospitalization for heart failure [2], and the onset of atrial fibrillation [3] due to electrical and 44 mechanical dyssynchrony. To address these issues, pacing techniques involving the His bundle 45 or left bundle area have been recently introduced [4,5]. Many studies have compared the outcomes 46 of these novel pacing techniques with those of conventional RVP [6], and investigated the factors 47 contributing to the problems associated with RVP, with pacing rate and QRS duration reported as 48 problematic factors [7,8]. However, to the best of our knowledge, studies on the relationship 49 between RVP and mortality are limited. The fibrosis-4 (FIB-4) index, a non-invasive marker used 50 to assess the degree of liver fibrosis, has been reported as a predictive factor for right ventricular 51 function and major adverse cardiovascular events in patients with heart diseases, such as heart 52 failure and tricuspid regurgitation [9,10]. In a study targeting heart failure in patients with 53 preserved left ventricular systolic function, those with a FIB-4 index \geq 3.11 had a 2.202-fold (95%) 54 confidence interval: 1.110-4.368) higher risk of major adverse cardiovascular events (composite 55 of cardiovascular death, heart failure-related rehospitalization, non-fatal myocardial infarction, 56 and non-fatal stroke) [10]. The FIB-4 index is related to cardiovascular events because prolonged 57 hepatic congestion due to reduced blood flow and sodium diuresis leads to fluid retention and 58 arterial sclerosis, which impair left ventricular diastolic function [10,11]. However, no study to 59 date has investigated the prognosis of patients with right ventricular pacemakers in relation to the 60 FIB-4 index. Therefore, this study aimed to investigate whether the FIB-4 index is associated with 61 mortality in patients with right ventricular pacemakers. Patients requiring pacemaker implantation 62 often have circulatory insufficiency and congestion at the time of bradycardia arrhythmia onset,

4

and many have elevated B-type natriuretic peptide (BNP) levels. If the FIB-4 index can be
 confirmed to independently predict prognosis, regardless of the pacing factors, it may have high
 clinical value.

66

67 Materials and Methods

68 Patients

69 This retrospective, single-center, observational study included patients who had undergone right ventricular pacemaker implantation for sinus node dysfunction or atrioventricular block between 70 71 April 2015 and December 2021. The following patients were excluded: 1) those who underwent 72 stimulation conduction system pacemaker implantation, such as His bundle pacing or left bundle area pacing; 2) those with a ventricular pacing rate < 1% at the final pacemaker check; 3) those 73 74 who did not undergo follow-up at our hospital after right ventricular pacemaker implantation; 4) those for whom right ventricular electrocardiograms were unobtainable (including only fusion 75 76 waveforms); and 5) those who underwent VVI-pacemaker implantation for bradycardia-induced 77 atrial fibrillation. Ultimately, 201 patients were included in the study.

The study was conducted in accordance with the standards of the Declaration of Helsinki and current ethical guidelines and was approved by the Ethics Committee on Medical Research of Chutoen General Medical Center (reference no: 1241230822). As this study was not a clinical trial, and the data were retrospectively and anonymously collected and analyzed, the requirement for patients' written informed consent was waived.

83 Data collection

84 The data were accessed for research purposes on August 23, 2023. The authors had access to

5

information that could identify individual participants during and after data collection. 85

86 The FIB-4 index was calculated based on the patient's age and blood test results at the time of pacemaker implantation using the following formula: FIB-4 index = age \times aspartate 87 88 aminotransferase [AST] level / (platelets × square root [alanine transaminase level]). The study participants were divided into three groups based on their FIB-4 index values: Tertile 1 (FIB-4 \leq 89 90 2.17; n = 67), Tertile 2 (2.18 \leq FIB-4 \leq 3.28; n = 67), and Tertile 3 (FIB-4 \geq 3.29; n = 67). Patient

91 characteristics were compared between the groups.

Primary and secondary outcomes 92

93 The primary outcome of this study was all-cause mortality, which included deaths due to cardiovascular disease, cancer, infections, and other causes. Secondary outcomes included 94 95 cardiovascular death, which comprised deaths resulting from fatal arrhythmias, fatal myocardial infarction, heart failure, and stroke, as well as non-cardiovascular death, which involved deaths 96 97 caused by non-cardiovascular factors like cancer, infections, and renal failure.

98

Electrocardiogram analysis

99 The 12-lead electrocardiograms (ECGs) obtained preoperatively and during pacemaker checks 100 were analyzed. ECGs were recorded at a paper speed of 25 mm/s and an amplitude of 10 mm/mV. 101 Two cardiologists independently evaluated the following parameters from each ECG: 1) the heart 102 rate; 2) the QRS duration (both during bradycardia, arrhythmias, and pacing); 3) the presence or 103 absence of conduction abnormalities.

Right ventricular pacemaker implantation and pacemaker check 104

105 Every patient underwent implantation of a dual-chamber pacemaker in the right ventricle (RV). 106 The specific site for RV lead implantation was the RV septum, aimed for under fluoroscopic 107 guidance. Nonetheless, the ultimate determination regarding lead placement was at the discretion

6

108 of the principal doctor, considering optimal electrical parameters and lead stability.

109 Pacemaker assessments were conducted prior, and subsequent, to implantation. Post-discharge,

110 patients received regular outpatient follow-ups at intervals of 6 to 9 months. During these visits,

appropriate ECG and pacemaker parameters were duly documented.

112 **Statistical analysis**

Regarding the statistical analysis, categorical variables were analyzed using the chi-square or Fisher's exact tests, and presented as numbers and percentages. Continuous variables were analyzed using non-parametric tests (Kruskal–Wallis test), and, if necessary, the Mann–Whitney U test was performed with the significance level adjusted using the Bonferroni method for multiple comparisons. The occurrence of mortality events during the post-implantation follow-up period was computed, and the curves depicting the incidence of these events were compared between groups utilizing log-rank assessment.

Univariate analysis using Cox proportional hazards was conducted for both primary and secondary outcomes. Multivariate analysis, adjusted for age and sex, was performed to determine the primary outcomes. Furthermore, multivariate analysis using the forced entry method was performed for other potential factors influencing clinical outcomes, such as the pacing rate during RVP, QRS duration, estimated glomerular filtration rate (eGFR), BNP level, and tricuspid regurgitation pressure gradient (TR-PG).

126 Statistical significance was set at P < 0.05. All statistical analyses were performed using R with 127 EZR software (Saitama Medical Center, Jichi Medical University, Saitama, Japan) [12]. 128 Regarding missing data, only the samples with complete data for individual statistical analyses 129 were included.

7

131 **Results**

Among patients who underwent pacemaker implantation at our hospital between April 2015 and
December 2021, 201 were included in the final analysis. In the comparison of the FIB-4 index

- tertiles, the median FIB-4 index values were as follows: Tertile 1, 1.80; Tertile 2, 2.66; and Tertile
- 135 3, 4.19 (P < 0.001). Significant differences were observed in various elements of the FIB-4 index,
- 136 including age, AST, platelet count, eGFR, hemoglobin, low-density lipoprotein cholesterol, BNP,
- 137 and dyslipidemia (Table 1).

No significant differences were observed in terms of baseline treatment, cardiac ultrasound examination results, or pacemaker parameters at the last follow-up. However, there was a significant difference in the proportion of left bundle branch block (LBBB) on the baseline ECG (Table 1).

142

143 Table 1. Patient characteristics according to the FIB-4 index tertiles

	Total	Tertile 1	Tertile 2	Tertile 3	<i>P</i> -value
		FIB-4≤2.17	2.18≤FIB-4≤3.28	FIB-4 ≥ 3.29	
	(n = 201)	(n = 67)	(n = 67)	(n = 67)	
Age, years	81 (73-87)	71 (67-80)	82 (76-87)	86 (80-89)	< 0.001
Sex, male, n (%)	102 (50)	33 (49)	35 (52)	34 (50)	0.98
Laboratory data					
AST, IU/L	26 (20-35)	22 (18-27)	26 (19-31)	33 (25-60)	< 0.001
ALT, IU/L	20 (13-31)	21 (14-29)	17 (13-27)	26 (13-53)	0.083
eGFR, mL/min/1.73 m ²	53.3 (39.1-63.8)	61.1 (45.7-72.0)	50.7 (40.8-63.7)	46.4 (34.2-56.8)	0.001
Hb, g/L	12.5 (11.1-13.8)	13.3 (11.9-14.5)	12.7 (11.3-14.0)	11.6 (10.3-12.9)	< 0.001
Plt, 10 ⁹ /L	18.6 (15.1-21.5)	21.4 (19.0-24.5)	18.0 (15.6-21.0)	14.8 (12.0-18.1)	< 0.001

FIB-4 index	2.66 (1.98-3.61)	1.80 (1.30-1.98)	2.66 (2.39-2.97)	4.19 (3.62-4.88)	< 0.001
LDL-C, mg/dL	100 (87–118)	108 (93–130)	95 (82–114)	96 (82–114)	0.001
HbA1c, %	6.1 (5.8-6.5)	6.1 (5.9-6.6)	6.0 (5.7–6.3)	6.0 (5.7-6.7)	0.080
BNP, pg/L	169 (58-464)	97 (46-213)	224(60-498)	369(118-592)	< 0.001
CV risk factors					
Hypertension, n (%)	130 (64)	44 (65)	46 (68)	40 (59)	0.58
Diabetes mellitus, n (%)	61 (30)	22 (32)	21 (31)	18 (26)	0.79
Dyslipidemia, n (%)	45 (22)	22 (32)	13 (19)	10 (14)	0.04
Smoking, n (%)	78 (38)	25 (37)	32 (47)	21 (31)	0.15
Post-PCI, n (%)	17 (8)	6 (8)	3 (4)	8 (11)	0.33
Prior MI, n (%)	12 (5)	3 (4)	3 (4)	6 (8)	0.60
AF, n (%)	39 (19)	15 (22)	14 (20)	10 (14)	0.52
Stroke, n (%)	27 (13)	12 (17)	10 (14)	5 (7)	0.18
COPD, n (%)	16 (7)	5 (7)	5 (7)	6 (8)	1
Treatment at baseline					
ACEI/ARB, n (%)	103 (51)	33 (49)	37 (55)	33 (49)	0.74
Beta-blockers, n (%)	21 (10)	6 (8)	8 (11)	7 (10)	0.95
CCB, n (%)	100 (49)	30 (44)	35 (52)	35 (52)	0.64
MRA, n (%)	14 (6)	2 (2)	8 (11)	4 (5)	0.14
Diuretics, n (%)	50 (24)	14 (20)	17 (25)	19 (28)	0.63
Statins, n (%)	58 (28)	26 (38)	18 (26)	14 (20)	0.07
Antiplatelets, n (%)	39 (19)	18 (26)	11 (16)	10 (14)	0.20
Oral anticoagulants, n	29 (14)	9 (13)	14 (20)	6 (8)	0.16
(%)					
Echocardiogram data at					
baseline					
LAD size, mm	41 (37-45)	41 (36-44)	42 (38-45)	41 (37-47)	0.33
LVEF, %	67 (60-72)	67 (59-72)	67 (59–71)	67 (63-72)	0.79

9

LVDd, mm	47 (43-51)	47 (44-51)	46 (43-50)	47 (43-52)	0.45
LVDs, mm	29 (26-32)	29 (27-32)	29 (26-32)	29 (26-33)	0.88
TR-PG, mmHg	26.8 (24.0-30.4)	26.1 (23.4-29.9)	26.8 (24.5-29.9)	29.0 (25.2-35.5)	0.007
ECG at baseline					
SND, n (%)	31 (15)	12 (17)	16 (23)	3 (4)	0.004
AVB, n (%)	170 (84)	55 (82)	51 (76)	64 (95)	
QRS duration, ms	120 (90-140)	122 (90-140)	118 (91-136)	122 (90-141)	0.78
RBBB , n (%)	94 (46)	33 (49)	33 (49)	28 (41)	0.64
LBBB, n (%)	16 (7)	5 (7)	1 (1)	10 (14)	0.016
LAHB, n (%)	35 (17)	11 (16)	12 (17)	12 (17)	1
LPHB, n (%)	10 (4)	5 (7)	3 (4)	2 (2)	0.61
ECG after RVP implant					
HR, bpm	69 (63-78)	69 (63-76)	69 (62-76)	72 (63-81)	0.36
QRS duration, ms	148 (138-160)	148 (136-160)	148 (138-158)	150 (138-163)	0.45
RVP parameters at final					
check					
Atrium					
Pacing rate, %	20 (5-48)	17 (6-40)	29 (6-55)	15 (4-45)	0.17
P-wave amplitude, mV	2.6 (1.6-3.9)	2.6 (1.7-4.0)	2.5 (1.4-4.0)	2.7 (1.6-3.7)	0.96
Threshold, V	0.6 (0.5-0.8)	0.7 (0.5-0.9)	0.6 (0.5-0.8)	0.6 (0.5-0.7)	0.15
Impedance, Ω	456 (399-539)	470 (418-540)	448 (399-520)	437 (380-560)	0.20
Ventricular					
Pacing rate, %	99 (67-100)	98 (51-100)	99 (27-100)	99 (95-100)	0.06
R-wave amplitude, mV	10.6 (7.9-14.8)	11.0 (7.9-14.8)	9.8 (7.6-14.5)	11.8 (7.8-14.8)	0.79
Threshold, V	0.8 (0.7-1.0)	0.8 (0.6-1.0)	0.8 (0.7-1.0)	0.8 (0.6-1.0)	0.51
Impedance, Ω	494 (440-571)	494 (437-565)	499 (458-585)	494 (433-573)	0.83

144 Data are presented as medians (interquartile ranges) for continuous variables and number of patients (n) and
 145 percentage (%). ACEI, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ALT, alanine

10

146	aminotransferase; ARB, angiotensin receptor blocker; AST, aspartate aminotransferase; AVB, atrioventricular
147	block; BNP, brain natriuretic protein; CCB, calcium channel blocker; COPD, chronic obstructive pulmonary
148	disease; CV, cardiovascular; eGFR, estimated glomerular filtration rate; FIB-4, fibrosis-4; Hb, hemoglobin;
149	HR, heart rate; LAD, left atrium diameter; LAHB, left anterior hemiblock; LBBB, left bundle branch block;
150	LDL, low-density lipoprotein; LPHB, left posterior hemiblock; LVDd, left ventricular end-diastolic diameter;
151	LVDs, left ventricular end-systolic diameter; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid
152	receptor antagonist; OMI, old myocardial infarction; PCI, percutaneous coronary intervention; RBBB, right
153	bundle branch block; SND, sinus node dysfunction; TR-PG, tricuspid regurgitant pressure gradient.
154	
155	Among the study patients (median age: 81 years), 38 died during the observation period (median:
156	1097 days), resulting in an incidence rate of 5.8/100 person-years. The incidence rates for each
157	major outcome, stratified into three groups based on the FIB-4 index, were as follows: Tertile 1,
158	2.9/100 person-years; Tertile 2, 2.3/100 person-years; and Tertile 3, 13.3/100 person-years (log-
159	rank test, <i>P</i> < 0.001; Fig 1A, Table 2).
160	Between-group comparisons for secondary outcomes, including cardiovascular and non-
161	cardiovascular death, were then performed. The incidence of cardiovascular death was as follows:
162	Tertile 1, 4/67 (5%); Tertile 2, 2/67 (2%); and Tertile 3, 7/67 (10%; log-rank test, <i>P</i> = 0.17; Fig
163	1B, Table 2). In contrast, the incidence of non-cardiovascular death was as follows: Tertile 1, 3/67
164	(4%); Tertile 2, 3/67 (4%); Tertile 3, 19/67 (28%), which was significantly different between the
165	groups (log-rank test, $P < 0.001$; Fig 1C, Table 2).
166	
167	Fig 1. All-cause mortality and secondary outcomes stratified by FIB-4 index tertiles
168	(A) Kaplan–Meier curve of all-cause mortality. (B) Cardiovascular death. (C) Non-cardiovascular

169 death. CVD, cardiovascular death; FIB-4, fibrosis-4.

11

		Total	Γ	Fertile 1]	Certile 2	Т	ertile 3
Outcome	(1	n = 201)	((n = 67)	((n = 67)	(1	n = 67)
	Events	Incidence rate	Events	Incidence rate	Events	Incidence rate	Events	Incidence rate
		(/100 person-		(/100 person-		(/100 person-		(/100 person-
		year)		year)		year)		year)
Primary outcome								
All-cause mortality	38	5.8	7	2.9	5	2.3	26	13.3
Secondary outcome								
CVD	13	2.0	4	1.6	2	0.9	7	3.5
Non-CVD	25	3.8	3	1.2	3	1.4	19	9.6

171 Table 2. Primary and secondary outcomes

172 Data are presented as number of patients (n). CVD, Cardiovascular death; FIB-4, Fibrosis-4.

173

In subgroup analysis of the association between overall mortality and the FIB-4 index, consistent
results were observed (Fig 2).

176

Fig 2. Forest plots from the subgroup analysis assessing the FIB-4 index and incidence of
all-cause mortality. BNP, B-type natriuretic peptide; CI, confidence interval; eGFR, estimated
glomerular filtration rate; FIB-4, fibrosis-4; Hb, hemoglobin; HR, hazard ratio; LBBB, left bundle
branch block; LVEF, left ventricular ejection fraction.

181

182 In the Cox proportional hazards analysis for all-cause mortality, based on the FIB-4 index with

183 Tertile 1 as the reference group, a significant increase in risk was observed in Tertile 3, with an

- unadjusted hazard ratio of 4.75 (95% CI: 2.05-11.0; P < 0.001; Table 3).
- 185 Subsequently, the adjusted hazard ratio, considering clinically important factors, such as age, sex,

12

186	and the presence or absence of LBBB at baseline; along with pacemaker-related factors, such as
187	QRS duration during pacing and ventricular pacing rate, was 4.02 (95% CI: 1.57–10.2; $P = 0.003$)
188	and 3.61 (95% CI: 1.37–9.48; $P = 0.009$) for Tertile 3 and Tertile 1, respectively (Table 3). In
189	contrast, the adjusted hazard ratio considering factors related to congestion, such as BNP, eGFR,
190	and TR-PG, was 3.47 (95% CI: 1.25–9.60; <i>P</i> = 0.016; Table 3).

192	Table 3. Cox	proportional	hazard analy	sis of the j	primary	outcome
-----	--------------	--------------	--------------	---------------------	---------	---------

Primary outcome	Hazard ratio	<i>P</i> -value
	(95% CI)	
Model 1: Unadjusted		
Tertile 1 (FIB-4 index \leq 2.17)	Reference	Reference
Tertile 2 (2.18 ≤ FIB-4 index ≤ 3.28)	0.81 (0.25-2.57)	0.73
Tertile 3 (FIB-4 index \geq 3.29)	4.75 (2.05-11.0)	< 0.001
Model 2: Adjusted for age and sex		
Tertile 1 (FIB-4 index≤ 2.17)	Reference	Reference
Tertile 2 (2.18 ≤ FIB-4 index ≤ 3.28)	0.69 (0.21-2.27)	0.55
Tertile 3 (FIB-4 index \geq 3.29)	4.02 (1.57-10.2)	0.003
Model 3: Adjusted for age, sex, LBBB at baseline, paced-QRSd		
and Vp rate at final check		
Tertile 1 (FIB-4 index≤2.17)	Reference	Reference
Tertile 2 (2.18 ≤ FIB-4 index ≤ 3.28)	0.68 (0.20-2.30)	0.54
Tertile 3 (FIB-4 index \geq 3.29)	3.61 (1.37-9.48)	0.009
Model 4: Adjusted for age. sex, BNP, eGFR and TR-PG		
Tertile 1 (FIB-4 index≤ 2.17)	Reference	Reference
Tertile 2 (2.18 ≤ FIB-4 index ≤ 3.28)	0.65 (0.19-2.22)	0.50

13

Tertile 3 (FIB-4 index \geq 3.29)	3.47 (1.25-9.60)	0.016
	5.17 (1.20 9.00)	0.010

193	Data are presented as hazard ratios and 95% confidence intervals. BNP, brain natriuretic protein; CI
194	confidence interval; eGFR, estimated glomerular filtration rate; FIB-4, fibrosis-4; LBBB, left bundle
195	branch block; QRSd, QRS duration; TR-PG, tricuspid regurgitant pressure gradient; Vp, ventricular pacing
196	
197	The evaluation of the predictive accuracy of the FIB-4 index for all-cause mortality was
198	performed using ROC curve analysis, resulting in an area under the curve of 0.72 (95% CI: 0.62-
199	0.82). The cut-off value for the FIB-4 index was 3.75, with a specificity of 0.86 and a sensitivity
200	of 0.63 (Fig 3).
201	
202	Fig 3. ROC curve analysis of the association between the FIB-4 index and the risk of all-
203	cause mortality. ROC, receiver operating characteristic; AUC, area under the curve.
204	

205 **Discussion**

This study showed that in patients with RVP implants, a high FIB-4 index was associated with an increased risk of all-cause mortality. This trend remained consistent even after adjusting for pacemaker-related factors. Furthermore, a rightward nonlinear relationship between the FIB-4 index and all-cause mortality was demonstrated. These findings are this study's novel contributions.

A meta-analysis compared cardiac resynchronization therapy and His/left bundle area pacing [13]; however, there is still a lack of studies specifically focusing on RVP and all-cause mortality. Spath et al. reported on a major composite endpoint, that included all-cause mortality, related to the lead position of RVP [14]; the all-cause mortality rate during the approximately 1000-day

14

215 follow-up period was approximately 20% of the analyzed participants, which was similar to the 216 death event rate in this study [14]. Subgroup analysis indicated that clinical outcomes improved when the ORS duration during pacing was narrow (< 130 ms) compared to when it was wide (>217 218 130 ms) [14]. Therefore, we hypothesized that pacemaker-related factors may significantly impact 219 mortality in patients with pacemakers and performed a multivariate analysis with pacing QRS 220 duration and ventricular pacing rate as confounding factors. However, the results of our study 221 revealed that the FIB-4 index was independently associated with all-cause mortality, regardless 222 of these factors.

223 We also evaluated the association between the FIB-4 index and cardiovascular death as a 224 secondary outcome. As mentioned earlier, RVP may significantly affect left ventricular 225 contraction and valvular pathology due to its nonphysiological pacing pattern, increasing the risk of heart failure and atrial fibrillation [1-3]. Considering that the FIB-4 index may reflect the 226 227 pathophysiology of circulatory failure, we hypothesized that there would be a significant 228 association between the FIB-4 index and cardiovascular death. Although the Kaplan-Meier 229 analysis showed no statistical significance, we believe that this might have been due to the 230 extremely low number of cardiovascular death events during the 3-year follow-up period.

Notably, advancements in medical therapy for heart failure reduced ejection fraction, transcatheter aortic valve replacement [15], MitraClip procedures for valvular disease [16], and interventional treatments for myocardial infarction. These factors, along with the widespread adoption of ablation therapy for atrial fibrillation, indicate that long-term follow-up is necessary for further analysis of cardiovascular death. Therefore, although no statistical differences in cardiovascular death were observed, the results of future studies are anticipated to shed light on the clinical significance of the FIB-4 index.

238 This study has some limitations. It was a retrospective single-center study; therefore, the influence

15

239 of potential biases, such as an imbalance in the patient population, cannot be denied. Moreover, 240 owing to the limited number of deaths, a multivariate analysis with sufficient consideration of 241 confounding factors could not be conducted. In addition, this study included patients with 242 sinoatrial node dysfunction, in whom the degree of fusion pacing may be affected by the delay 243 settings, which could potentially affect the clinical outcomes. Lastly, although the ventricular 244 pacing rate is an important factor in clinical outcomes, this study only considered the pacing rate at the final follow-up. In reality, there may be long-term variations in the pacing rates for each 245 246 patient, and it is necessary to investigate the relationship between temporal pacing rate changes 247 and death events.

248 **Conclusion**

In summary, the FIB-4 index may be a potential predictor of overall mortality in patients withright ventricular pacemakers.

252 Acknowledgments

We are grateful to Dr. Takahiro Imaizumi for helpful discussions and comments on the manuscript.

255 Authors' Contributions

- 256 Naoya Inoue: Conceptualization, data curation, methodology, project administration,
- 257 visualization, writing original draft, writing review & editing.
- 258 Shuji Morikawa: Formal analysis, writing review & editing.
- 259 Takashi Ogane: Data curation, writing review & editing.
- Takehiro Hiramatsu: Data curation, conceptualization, formal analysis, investigation. writing –
 review & editing.
- 262 Toyoaki Murohara: Conceptualization, supervision, validation, writing original draft, writing –
 263 review & editing.
- 264

265 **References**

- 266 1. Ponnusamy SS, Syed T, Vijayaraman P. Pacing induced cardiomyopathy: recognition and
- 267 management. Heart. 2023;109: 1407-1415. doi: 10.1136/heartjnl-2022-321723.
- 268 2. Tayal B, Fruelund P, Sogaard P, Riahi S, Polcwiartek C, Atwater BD, et al. Incidence of heart
- failure after pacemaker implantation: a nationwide Danish registry-based follow-up study.
- 270 Eur Heart J. 2019;40: 3641-3648. doi: 10.1093/eurheartj/ehz584.
- 271 3. Zhu H, Li X, Wang Z, Liu Q, Chu B, Yao Y, et al. New-onset atrial fibrillation following left
- bundle branch area pacing vs. right ventricular pacing: a two-centre prospective cohort study.
- 273 Europace. 2023;25: 121-129. doi: 10.1093/europace/euac132.
- Zhang S, Zhou X, Gold MR. Left bundle branch pacing: JACC Review Topic of the Week.
 J Am Coll Cardiol. 2019;74: 3039-3049. doi: 10.1016/j.jacc.2019.10.039.
- 276 5. Zhang W, He L, Zhang J, Fu G, Sheng X, Pan Y, et al. Electrical synchrony optimization for
- left bundle branch area pacing in patients with bradycardia and heart failure. Am J Cardiol.
- 278 2023;203: 436-443. doi: 10.1016/j.amjcard.2023.07.017.
- 279 6. Palmisano P, Ziacchi M, Dell'Era G, Donateo P, Ammendola E, Coluccia G, et al. Rate and
- 280 nature of complications of conduction system pacing compared with right ventricular pacing:
- results of a propensity score-matched analysis from a multicenter registry. Heart Rhythm.
- 282 2023;20: 984-991. doi: 10.1016/j.hrthm.2023.03.009.
- Yu Z, Liang Y, Xiao Z, Wang Y, Bao P, Zhang C, et al. Risk factors of pacing dependence
 and cardiac dysfunction in patients with permanent pacemaker implantation. ESC Heart Fail.
 2022;9: 2325-2335. doi: 10.1002/ehf2.13918.
- 8. Qian Z, Wang Y, Hou X, Qiu Y, Wu H, Zhou W, et al. Efficacy of upgrading to left bundle
 branch pacing in patients with heart failure after right ventricular pacing. Pacing Clin

288 Electrophysiol. 2021;44: 472-480. doi: 10.1111/pace.14147.

- 289 9. Nakashima M, Tanakaya M, Miyoshi T, Saito T, Katayama Y, Sakuragi S, et al. The fibrosis-
- 4 index predicts cardiovascular prognosis in patients with severe isolated tricuspid
 regurgitation. Circ J. 2022;86: 1777-1784. doi: 10.1253/circj.CJ-22-0109.
- 10. Nakashima M, Sakuragi S, Miyoshi T, Takayama S, Kawaguchi T, Kodera N, et al. Fibrosis-4
 index reflects right ventricular function and prognosis in heart failure with preserved ejection
- fraction. ESC Heart Fail. 2021;8: 2240-2247. doi: 10.1002/ehf2.13317.
- Pais R, Redheuil A, Cluzel P, Ratziu V, Giral P. Relationship among fatty liver, specific and
 multiple-site atherosclerosis, and 10-year Framingham score. Hepatology. 2019;69: 14531463. doi: 10.1002/hep.30223.
- 12. Kanda Y. Investigation of the freely available easy-to-use software "EZR" for medical
 statistics. Bone Marrow Transplant. 2013;48: 452-458. doi: 10.1038/bmt.2012.244.
- Abdin A, Aktaa S, Vukadinović D, Arbelo E, Burri H, Glikson M, et al. Outcomes of
 conduction system pacing compared to right ventricular pacing as a primary strategy for
 treating bradyarrhythmia: systematic review and meta-analysis. Clin Res Cardiol. 2022;111:
- 303 1198-1209. doi: 10.1007/s00392-021-01927-7.
- 304 14. Spath NB, Wang K, Venkatasumbramanian S, Fersia O, Newby DE, Lang CC, et al.
 305 Complications and prognosis of patients undergoing apical or septal right ventricular pacing.
 306 Open Heart. 2019;6: e000962. doi: 10.1136/openhrt-2018-000962.
- 307 15. Schewel J, Schlüter M, Schmidt T, Kuck KH, Frerker C, Schewel D. Early haemodynamic
 308 changes and long-term outcome of patients with severe low-gradient aortic stenosis after
 309 transcatheter aortic valve replacement. EuroIntervention. 2020;15: 1181-1189. doi:
 310 10.4244/EIJ-D-19-00399.
- 311 16. Mack MJ, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al. 3-year outcomes

- 312 of transcatheter mitral valve repair in patients with heart failure. J Am Coll Cardiol. 2021;77:
- 313 1029-1040. doi: 10.1016/j.jacc.2020.12.047.

314

315 Supporting information

316 S1 Table. Anonymous dataset of 201 patients.



Figure

(which was not certified by peer re	It is made available under a CC-BY 4.0 International licens	Forest plot	HR	95%-CI
ALL			1.43	[1.16; 1.77]
Age	< median (81 years)		1.86	[1.22; 2.86]
	<u>≥</u> median		1.21	[0.94; 1.54]
Sex	Female		1.32	[0.99; 1.75]
	Male		1.56	[1.15; 2.11]
eGFR at baseline	< 60 mL/min/1.73m ²		3.77	[1.70; 8.36]
	≧ 60 mL/min/1.73m ²		1.21	[0.97; 1.50]
Hb at baseline	≧ median (12.5 g/L)		1.57	[1.10; 2.26]
	< median		1.29	[0.99; 1.67]
Platelet at baseline	≥ median (18.6*10 ⁹ /L)		1.84	[1.18; 2.88]
	< median		1.25	[0.97; 1.61]
BNP at baseline	< median (169 pg/L)		1.85	[1.26; 2.73]
	<u>≥</u> median		1.13	[0.87; 1.46]
Dyslipidemia	No		1.43	[1.11; 1.84]
	Yes		1.48	[0.96; 2.28]
Smoking	No		1.42	[1.10; 1.84]
	Yes	- <u>i</u>	1.82	[1.15; 2.88]
LVEF at baseline	≧ 60%		1.31	[1.05; 1.63]
	< 60%		3.08	[1.44; 6.60]
Bradyarrhythmias	Sinus node dysfunction		3.63	[1.09; 12.1]
	Atrioventricular block		1.34	[1.09; 1.66]
LBBB at baseline	No		1.47	[1.16; 1.86]
	Yes		1.07	[0.60; 1.92]
QRS duration after	< median (148ms)		1.37	[0.99; 1.88]
right ventricular pacing	≧ median		1.49	[1.11; 2.00]
	Common effect model		1.40	[1.32; 1.49]
	Random effects model	\ \	1.40	[1.32; 1.49]
			I	
	0.1	0.5 1 2 1	0	

Figure



Figure